Shopping Cart 0
Cart Subtotal
USD 0

Kadmon Corp LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Kadmon Corp LLC (Kadmon) is a biopharmaceutical company that offers products and related services for the management and treatment of hepatitis C. The company also develops therapies for metabolic and serious diseases. Its products include ribavirin, USP Tablets, ribavirin capsules, phentermine and topiramate extended-release capsules and trientine hydrochloride. Kadmon offers products in the therapeutic areas of oncology, infectious diseases, immunology, and neurodegenerative disease. The company's discovery platforms include metabolomics, chromics, monoclonal antibodies, synthetic biology and gene regulation. It undertakes identification and evaluation of investigational compounds, which show the potential to improve patient outcomes. Kadmon is headquartered in New York, the US.

Kadmon Corp LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Kadmon Acquires Rights To Salirasib From Concordia Pharma 12

Venture Financing 13

Kadmon Raises USD5.7 Million in Venture Financing 13

Kadmon Raises US$4.7 Million In Venture Financing 13

Kadmon Pharma Secures US$40 Million In Venture Financing 14

Partnerships 15

Kadmon Amends Distribution Agreement with Camber Pharma 15

Kadmon Enters into R&D Agreement with NIDCR 15

EffRx Pharma Enters An Agreement With Kadmon 16

Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 17

Kadmon Pharma Forms Joint Venture With Nano Terra 18

Licensing Agreements 19

Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 19

Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 20

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 21

Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 22

Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 23

Dyax Enters Into Licensing Agreement With Kadmon 24

Equity Offering 25

Kadmon Plans to Raise Funds through Public Offering of Shares 25

Kadmon Prices IPO for USD75 Million 26

Kadmon Raises USD11 Million in Private Placement of Units 27

Kadmon Raises USD5.5 Million in Private Placement of Units 28

Kadmon Raises USD10 Million in Private Placement of Units 28

Kadmon Raises USD35 Million in Private Placement of Units 29

Kadmon Raises USD15 Million in Private Placement of Units 30

Asset Transactions 30

AbbVie Acquires Rights to Ribasphere from Kadmon 30

Acquisition 31

MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 31

Kadmon Corp LLC-Key Competitors 33

Key Employees 34

Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

Sep 07, 2016: Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016 36

Clinical Trials 37

Apr 14, 2016: Kadmon to Present Preclinical Data Demonstrating that its Novel Immuno-Oncology Compound Achieves Long-Lasting and Persistent Antitumor Immunity 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9


List Of Table

List of Tables

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Key Facts 1

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Kadmon Corp LLC, Deals By Therapy Area, 2011 to YTD 2017 9

Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Kadmon Acquires Rights To Salirasib From Concordia Pharma 12

Kadmon Raises USD5.7 Million in Venture Financing 13

Kadmon Raises US$4.7 Million In Venture Financing 13

Kadmon Pharma Secures US$40 Million In Venture Financing 14

Kadmon Amends Distribution Agreement with Camber Pharma 15

Kadmon Enters into R&D Agreement with NIDCR 15

EffRx Pharma Enters An Agreement With Kadmon 16

Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 17

Kadmon Pharma Forms Joint Venture With Nano Terra 18

Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 19

Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 20

AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 21

Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 22

Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 23

Dyax Enters Into Licensing Agreement With Kadmon 24

Kadmon Plans to Raise Funds through Public Offering of Shares 25

Kadmon Prices IPO for USD75 Million 26

Kadmon Raises USD11 Million in Private Placement of Units 27

Kadmon Raises USD5.5 Million in Private Placement of Units 28

Kadmon Raises USD10 Million in Private Placement of Units 28

Kadmon Raises USD35 Million in Private Placement of Units 29

Kadmon Raises USD15 Million in Private Placement of Units 30

AbbVie Acquires Rights to Ribasphere from Kadmon 30

MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 31

Kadmon Corp LLC, Key Competitors 33

Kadmon Corp LLC, Key Employees 34

Kadmon Corp LLC, Other Locations 35

Kadmon Corp LLC, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kadmon Corp LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.